Multi-targeted agents in cancer cell chemosensitization: What we learnt from curcumin thus far

Recent Patents on Anti-Cancer Drug Discovery

Volumn 11, Issue 1, 2016, Pages 67-97

  Bordoloi, Devivasha ^a   Roy, Nand K ^a   Monisha, Javadi ^a   Padmavathi, Ganesan ^a   Kunnumakkara, Ajaikumar B ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

Cancer; Chemoresistance; Chemosensitization; Combination therapy; Curcumin; Multi targeted therapy

Indexed keywords

ARCTIGENIN; CARNOSIC ACID; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EMODIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GENISTEIN; GRAMICIDIN; KI 67 ANTIGEN; LIMONOID; MITOMYCIN; OUABAIN; PACLITAXEL; RETINOIC ACID; SILIBININ; TAMOXIFEN; TEMOZOLOMIDE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ULINASTATIN; VINBLASTINE; VORINOSTAT; WORTMANNIN; ANTINEOPLASTIC AGENT; AUTACOID; TRANSCRIPTION FACTOR;

ARTICLE; BIOLOGICAL ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CELL; CHEMOSENSITIZATION; COLON CANCER; CURCUMA LONGA; DRUG BIOAVAILABILITY; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; HYBRID; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; NONHUMAN; PATENT; PRIORITY JOURNAL; STOMACH CANCER; UTERINE CERVIX CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASMS; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION MEDIATORS; NEOPLASMS; PATENTS AS TOPIC; TRANSCRIPTION FACTORS;

EID: 84958987176     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892810666151020101706     Document Type: Article

References (253)

1. Ding J, Feng Y, Wang HY. From cell signaling to cancer therapy. Acta Pharmacol Sin 2007; 28: 1494-8.
2. Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR, et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 1991; 11: 1785-92.
3. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-56.
4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. (2013) GLOBOCAN 2012, GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http: //globocan. iarc. fr.
5. Aggarwal B, Prasad S, Sung B, Krishnan S, Guha S. Prevention and treatment of colorectal cancer by natural agents from mother nature. Curr Colorectal Cancer Rep 2013; 9: 37-56.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-74.
7. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006; 13: 751-78.
8. Frantz S. Drug discovery: Playing dirty. Nature 2005; 437: 942-3.
9. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: An emerging approach for cancer therapy. Drug Discov Today 2012; 17: 1044-52.
10. Vogel A, Pelletier J. Examen chimique de la racine de Curcuma. J Pharm 1815; 1: 289-300.
11. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39: 283-99.
12. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007; 255: 170-81.
13. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
14. Vadhan-Raj S, Wang M, Giralt S, Alexanian R, Thomas S, Zhou X, et al. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a Phase I/II Study. Blood 2007; 110: Abstract 1177.
15. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-64.
16. Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. Eur J Cancer 2005; 41: 1955-68.
17. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
18. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008; 75(4): 787-809.
19. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007; 4: 807-18.
20. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267: 133-64.
21. Azuine MA, Bhide SV. Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. J Ethnopharmacol 1994; 44: 211-7.
22. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002; 64: 573-82.
23. Pichu S, Krishnamoorthy S, Shishkov A, Zhang B, McCue P, Ponnappa BC. Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition. PLoS One 2012; 7: e48567.
24. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Pharmacol 2010; 79: 218-28.
25. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 2009; 69: 8958-66.
26. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factorkappaB-regulated gene products in IFN-alpha-sensitive and IFN alpha-resistant human bladder cancer cells. Mol Cancer Ther 2007; 6: 1022-30.
27. Dilnawaz F, Sahoo SK. Enhanced accumulation of curcumin and temozolomideloaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur J Pharm Biopharm 2013; 85: 452-62.
28. Ramachandran C, Nair SM, Escalon E, Melnick SJ. Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor celllines. J Complement Integr Med 2012; 9: doi: 10. 1515/1553-3840. 1614.
29. Hossain M, Banik NL, Ray SK. Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int 2012; 61; 1102-13.
30. Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky SA. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2Lmediated apoptosis through activation of procaspases and release of cytochrome C from mitochondria. J Exp Ther Oncol 2005; 5: 39-48.
31. Chung SS, Vadgama JV. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res 2015; 35: 39-46.
32. Rao DK, Liu H, Ambudkar SV, Mayer M. A combination of curcumin with either gramicidin or ouabain selectively kills cells that express the multidrug resistance-linked ABCG2 transporter. J Biol Chem 2014; 289: 31397-410.
33. Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV, et al. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv 2014; 4: 35242-50.
34. Wang S, Chen R, Zhong Z, Shi Z, Chen M, Wang Y. Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells. Am J Chin Med 2014; 42: 1279-300.
35. Zhou QM, Chen QL, Du J, Wang XF, Lu YY, Zhang H, et al. Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: A cDNA microarray analysis. Int J Mol Sci 2014; 15: 16284-301.
36. Zhan Y, Chen Y, Liu R, Zhang H, Zhang Y. Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling. Arch Pharm Res 2014; 37: 1086-95.
37. Thulasiraman P, McAndrews DJ, Mohiudddin IQ. Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells. BMC Cancer 2014; 14: 724.
38. Meiyanto E, Putri DD, Susidarti RA, Murwanti R, Sardjiman, Fitriasari A, et al. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev 2014; 15: 179-84.
39. Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, Abhari A, Dariushnejad H. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev 2014; 14: 6595-9.
40. Chen WC, Lai YA, Lin YC, Ma JW, Huang LF, Yang NS, et al. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem 2013; 61: 11817-24.
41. Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z, Terry C, et al. Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer 2013; 13: 418.
42. Nasiri M, Zarghami N, Koshki KN, Mollazadeh M, Moghaddam MP, Yamchi MR, et al. Curcumin and silibinin inhibittelomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev 2013; 14: 3449-53.
43. Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F, Altuntas CZ, et al. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymercomplexation in human cancer cells. Mol Pharm 2013; 10: 2676-83.
44. Guo J, Li W, Shi H, Xie X, Li L, Tang H, et al. Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem 2013; 382: 103-11.
45. Park S, Cho DH, Andera L, Suh N, Kim I. Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. Mol Cell Biochem 2013; 383: 39-48.
46. Bayet-Robert M, Morvan D. Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLoS One 2013; 8: e57971.
47. Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, et al. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules 2013; 18(1): 701-20.
48. Guo X, Yin S, Dong Y, Fan L, Ye M, Lu J, et al. Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: Potential role of Mcl-1 and FAK. Mol Carcinog 2013; 52: 879-89.
49. Yan G, Graham K, Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog 2013; 52: 404-11.
50. Einbond LS, Wu HA, Kashiwazaki R, He K, Roller M, Su T, et al. Carnosic acid inhibits the growth of ER-negative human breast cancer cells and synergizes with curcumin. Fitoterapia 2012; 83: 1160-8.
51. Lin KT, Wang YW, Chen CT, Ho CM, Su WH, Jou YS. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clin Cancer Res 2012; 18: 4691-701.
52. Duan, J, Mansour HM, Zhang Y, Deng X, Chen Y, Wang J, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2012; 426: 193-201.
53. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, Su SB. Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. Acta Pharmacol Sin 2011; 32: 1402-10.
54. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, Huang S, et al. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. Eur J Cancer 2011; 47: 2240-7.
55. Roy M, Mukherjee S, Sarkar R, Biswas J. Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NFkappaB and HDAC in breast cancer. Ther Deliv 2011; 2: 1275-93.
56. Altenburg JD, Bieberich AA, Terry C, Harvey KA, Vanhorn JF, Xu Z, et al. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: Unique signaling not explained by the effects of either compound alone. BMC. Cancer 2011; 11: 149.
57. Dayton A, Selvendiran K, Meduru S, Khan M, Kuppusamy ML, Naidu S, et al. Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867. J Pharmacol Exp Ther 2011; 339: 350-7.
58. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, et al. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 2011; 286: 42232-447.
59. Cheah YH, Nordin FJ, Sarip R, Tee TT, Azimahtol HL, Sirat HM, et al. Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231. Cancer Cell Int 2009; 9: 1.
60. Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J 2009; 15: 223-9.
61. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ, et al. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int J Cancer 2008; 122: 1966-71.
62. Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006; 5: 952-61.
63. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, et al. Curcumin suppresses the paclitaxelinduced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11(20): 7490-8.
64. Verma SP, Salamone E, Goldin B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem Biophys Res Commun 1997; 233: 692-96.
65. Bava SV, Sreekanth CN, Thulasidasan AK, Anto NP, Cheriyan VT, Puliyappadamba VT, et al. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol 2011; 43: 331-41.
66. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51-9.
67. Anitha A, Sreeranganathan M, Chennazhi KP, Lakshmanan VK, Jayakumar R. In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N, O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies. Eur J Pharm Biopharm 2014; 88: 238-51.
68. Anitha A, Deepa N, Chennazhi KP, Lakshmanan VK, Jayakumar R. Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. Biochim Biophys Acta 2014; 1840: 2730-43.
69. Shakibaei M, Buhrmann C, Kraehe P, Shayan P, Lueders C, Goel A. Curcumin chemosensitizes 5-fluorouracil resistant MMRdeficient human colon cancer cells in high density cultures. PLoS One 2014; 9: e85397.
70. Kantara C, O'Connell M, Sarkar S, Moya S, Ullrich R, Singh P. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA. Cancer Res 2014; 74: 2487-98.
71. Shen F, Cai WS, Li JL, Feng Z, Liu QC, Xiao HQ, et al. Synergism from the combination of ulinastatin and curcumin offers greater inhibition against colorectal cancer liver metastases via modulating matrix metalloproteinase-9 and E-cadherin expression. Onco Targets Ther 2014; 7: 305-14.
72. Chidambara MKN, Jayaprakasha GK, Patil BS. Citrus limonoids and curcumin additively inhibit human colon cancer cells. Food Funct 2013; 4: 803-10.
73. Shakibaei M, Mobasheri A, Lueders C, Busch F, Shayan P, Goel A. et al. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. PLoS One 2013; 8: e57218.
74. Noratto GD, Jutooru I, Safe S, Angel-Morales G, Mertens-Talcott SU. The drug resistance suppression induced by curcuminoids in colon cancer SW-480 cells is mediated by reactive oxygen speciesinduced disruption of the microRNA-27a-ZBTB10-Sp axis. Mol Nutr Food Res 2013; 57: 1638-48.
75. Yu Y, Sarkar FH, Majumdar AP. Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 2013; 6: 180-6.
76. Lu WD, Qin Y, Yang C, Li L, Fu ZX. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics (Sao Paulo) 2013; 68: 694-701.
77. Fenton JI, McCaskey SJ. Curcumin and docosahexaenoic acid blockinsulin-induced colon carcinoma cell proliferation. Prostaglandins Leukot. Essent Fatty Acids 2013; 88: 219-26.
78. Manikandan R, Beulaja M, Arulvasu C, Sellamuthu S, Dinesh D, Prabhu D, et al. Synergistic anticancer activity of curcumin and catechin: An in vitro study using human cancer cell lines. Microsc Res Tech 2012; 75: 112-6.
79. Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res 2012; 56: 454-65.
80. Srimuangwong K, Tocharus C, Yoysungnoen CP, Suksamrarn A, Tocharus J. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol 2012; 18: 2383-9.
81. Nautiyal J, Kanwar SS, Yu Y, Majumdar AP. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal 2011; 6: 7.
82. Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, et al. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer 2011; 128: 951-61.
83. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP, et al. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2009; 2: 321-8.
84. Giri B, Gomes A, Sengupta R, Banerjee S, Nautiyal J, Sarkar FH, et al. Curcumin synergizes the growth inhibitory properties of Indian toad (Bufo melanostictus Schneider) skin-derived factor (BMANF1) in HCT-116 colon cancer cells. Anticancer Res 2009; 29: 395-401.
85. Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, Du J, et al. Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer 2009; 61: 544-53.
86. Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009; 125: 2187-97.
87. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, Rishi AK, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 2008; 122: 267-73.
88. Telang N, Katdare M. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer. Oncol Rep 2007; 17: 909-14.
89. Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006; 52: 23-8.
90. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11: 6738-44.
91. Rashmi R, Kumar S, Karunagaran D. Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 2004; 25: 179-87.
92. Ye F, Zhang GH, Guan BX, Xu XC. Suppression of esophageal cancer cell growthusing curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol 2012; 18: 126-35.
93. Tian F, Fan T, Zhang Y, Jiang Y, Zhang X. Curcumin potentiates the anti-tumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 847-55.
94. Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, et al. Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 2010; 3: 99-108.
95. Zhou X, You T, Wang WM, Zheng ZQ. Curcumin combined FOLFOX induced cell apoptosis of gastric cancer and its mechanism research. Zhongguo Zhong Xi Yi Jie He Za Zhi 2013; 33: 810-3.
96. Yu LL, Wu JG, Dai N, Yu HG, Si JM. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor. Oncol Rep 2011; 26: 1197-203.
97. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005; 26: 1009-16.
98. Koo JY, Kim HJ, Jung KO, Park KY. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 2004; 7: 117-21.
99. Masuelli L, Di Stefano E, Fantini M, Mattera R, Benvenuto M, Marzocchella L, et al. Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget 2014; 5: 10745-62.
100. Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P. et al. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PLoS One 2014; 9: e93208.
101. Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, et al. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg 2011; 137 (5): 499-507.
102. Duarte VM, Han E, Veena MS, Salvado A, Suh JD, Liang LJ, et al. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol Cancer Ther 2010; 9: 2665-75.
103. Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG. Quantitation of chemopreventive synergism between (-) epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 1998; 19: 419-24.
104. Seo BR, Min KJ, Cho IJ, Kim SC, Kwon TK. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVPBEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One 2014; 9: e95588.
105. Jung, E. M. Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5g(DR5). Carcinogenesis 2005; 26: 1905-13.
106. Fan JX, Zeng YJ, Wu JW, Li ZQ, Li YM, Zheng R, et al. Synergistic killing effect of arsenic trioxide combined with curcumin on KG1a cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2014; 22: 1267-72.
107. Sarkar R, Mukherjee A, Mukherjee S, Biswas R, Biswas J, Roy M. Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6. J Environ Pathol Toxicol Oncol 2014; 33: 247-63.
108. Chen TY, Xu F, Kong YY, Wen F, Xie FY, Wan LG, et al. Effect of curcumincombined with ATRA on differentiation of ATRAresistant acute promyelocytic leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013; 21: 895-98.
109. Pedroso LS, Fávero GM, de Camargo LE, Mainardes RM, Khalil NM. Effect of theo-methyl catechols apocynin, curcumin and vanillin on the cytotoxicity activity of tamoxifen. J Enzyme Inhib Med Chem 2013; 28: 734-40.
110. Papiez MA. The influence of curcumin on the action of etoposide in a rat acute myeloid leukemia cell line. Folia Med Cracov 2013; 53: 61-72.
111. Dhanasekaran S, Biswal BK, Sumantran VN, Verma RS. Augmented sensitivity to methotrexate by curcumin induced overexpression of folate receptor in KG-1 cells. Biochimie 2013; 95: 1567-73.
112. El-Houseini ME, Refaei MO, Amin AI, Abol-Ftouh MA. Potential role of curcumin and taurine combination therapy on human myeloid leukemic cells propagated in vitro. Leuk. Lymphoma 2013; 54: 2281-7.
113. Pesakhov S, Khanin M, Studzinski GP, Danilenko M. Distinct combinatorial effects of the plant polyphenols curcumin, carnosic acid, and silibinin on proliferation and apoptosis in acute myeloid leukemia cells. Nutr Cancer 2010; 62: 811-24.
114. Sánchez Y, Simón GP, Calviño E, de Blas E, Aller P. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J Pharmacol Exp Ther 2010; 335: 114-23.
115. Chen J, Wang G, Wang L, Kang J, Wang J. Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells. Eur J Pharm Sci 2010; 41: 210-8.
116. Saxena A, Saxena AK, Singh J, Bhushan S. Natural antioxidants synergistically enhance the anticancer potential of AP9-cd, a novel lignan composition from Cedrus deodara in human leukemia HL-60 cells. Chem Biol Interact 2010; 188: 580-90.
117. Hayun R, Okun E, Berrebi A, Shvidel L, Bassous L, Sredni B, et al. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk. Lymphoma 2009; 50: 625-32.
118. Zhang KZ, Xu JH, Huang XW, Wu LX, Su Y, Chen YZ. et al. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacol Sin 2007; 28: 105-10.
119. Chang HY, Pan KL, Ma FC, Jiao XY, Zhu HF, Liu JH, et al. The study on reversing mechanism of multidrug resistance of K562/A02 cell line by curcumin and erythromycin. Zhonghua Xue Ye Xue Za Zhi 2006; 27: 254-8.
120. Chen J, Bai H, Wang C, Kang J. Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 2006; 61: 710-6.
121. Sokoloski JA, Sartorelli AC. Induction of the differentiation of HL-60 promyelocytic leukemia cells by curcumin in combination with low levels of vitamin D3. Oncol Res 1997; 9: 31-9.
122. Xiao H, Zhang KJ. Antiproliferative effect of curcumin combined with cyclophosmide on the growth of human lymphoma cell line HT/CTX with drug resistance and its relation with FA/BRCA pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16: 804-8.
123. Zhao X, Chen Q, Liu W, Li Y, Tang H, Liu X, et al. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer. Int J Nanomedicine 2014; 10: 257-70.
124. Du Q, Hu B, An HM, Shen KP, Xu L, Deng S, et al. Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells. Oncol Rep 2013; 29: 1851-8.
125. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology 2013; 57: 1847-57.
126. Huang CS, Ho CT, Tu SH, Pan MH, Chuang CH, Chang HW, et al. Long-term ethanol exposure-induced hepatocellular carcinoma cell migration and invasion through lysyl oxidase activation are attenuated by combined treatment with pterostilbene and curcumin analogues. J Agric Food Chem 2013; 61: 4326-35.
127. Zhu R, Wu X, Xiao Y, Gao B, Xie Q, Liu H, et al. Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line. Cancer Biother Radiopharm 2013; 28: 579-87.
128. Abd-Rabou AA, Zoheir KM, Ahmed HH. Potential impact of curcumin and taurine on human hepatoma cells using Huh-7 cell line. Clin Biochem 2012; 45: 1519-21.
129. Qian H, Yang Y, Wang X. Curcumin enhanced adriamycininduced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci 2011; 43: 125-31.
130. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005; 224: 53-65.
131. Chen P, Li J, Jiang HG, Lan T, Chen YC. Curcumin reverses cisplatin resistance in cisplatin-resistant lung cancer cells by inhibiting FA/BRCA pathway. Tumour Biol 2014; 36(5): 3591-9.
132. Chen PM, Cheng YW, Wu TC, Chen CY, Lee H. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway. Free Radic Biol Med 2014; 79C: 127-37.
133. Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, et al. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncol Res 2013; 21: 137-44.
134. Yamauchi Y, Izumi Y, Yamamoto J, Nomori H. Co administration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells. Phyto Ther Res 2014; 28: 728-35.
135. Choudhury D, Ganguli A, Dastidar DG, Acharya BR, Das A, Chakrabarti G. et al. Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulin. Biochimie 2013; 95: 1297-309.
136. Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. et al. Combination of low concentration of (-)-Epigallocatechin Gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest. Int J Mol Sci 2013; 14: 12023-36.
137. Wang BL, Shen YM, Zhang QW, Li YL, Luo M, Liu Z, et al. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer. Int J Nanomedicine 2013; 8: 3521-31.
138. Ye MX, Zhao YL, Li Y, Miao Q, Li ZK, Ren XL, et al. Curcumin reverses cisplatin resistance and promotes human lung adenocarcinoma A549/DDPcell apoptosis through HIF-1α and caspase-3 mechanisms. Phytomedicine 2012; 19: 779-87.
139. Rocks N, Bekaert S, Coia I, Paulissen G, Gueders M, Evrard B, et al. Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer 2012; 107: 1083-92.
140. Yin H, Guo R, Xu Y, Zheng Y, Hou Z, Dai X, et al. Synergistic antitumor efficiency of docetaxel and curcumin against lung cancer. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 147-53.
141. Weng SH, Tsai MS, Chiu YF, Kuo YH, Chen HJ, Lin YW. et al. Enhancement of mitomycinC-induced cytotoxicity by curcumin re sults from down-regulation ofMKK1/2-ERK1/2-mediated thymidine phosphorylase expression. Basic Clin Pharmacol Toxicol 2012; 110: 298-306.
142. Lin H, Kuo LK, Chuu CP. Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells. Phytother Res 2012; 26: 122-6.
143. Ko JC, Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW. et al. Curcumin enhances themitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol 2011; 255: 327-38.
144. Tsai MS, Weng SH, Kuo YH, Chiu YF, Lin YW. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Mol Pharmacol 2011; 80: 136-46.
145. Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, et al. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation inintestine: The versatile adjuvant for gefitinib therapy. PLoS One 2011; 6: e23756.
146. Ikeda R, Vermeulen LC, Lau E, Jiang Z, Pomplun M, Kolesar JM. Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells. Mol Med Rep 2010; 3: 1031-4.
147. Tang N, Zhang J, Du Y. Curcumin promoted the apoptosis of cisplain-resistant human lung carcinoma cells A549/DDP through down-regulating miR-186*. Zhongguo Fei Ai Za Zhi 2010; 13: 301-6.
148. Thomas SL, Zhao J, Li Z, Lou B, Du Y, Purcell J, et al. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol 2010; 80: 1309-16.
149. Saha A, Kuzuhara T, Echigo N, Suganuma M, Fujiki H. New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin. Cancer Prev Res (Phila) 2010; 3: 953-62.
150. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y. Curcumin sensitizes lung cancer cells tocisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Invest 2009; 27: 624-35.
151. Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S, et al. Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 2008; 7: 1024-32.
152. Sen S, Sharma H, Singh N. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 2005; 331: 1245-52.
153. Bai, QX, Zhang XY. Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: Potential roles of NF-κB/JNK. Int J Mol Sci 2012; 13: 4831-8.
154. Mujtaba T, Kanwar J, Wan SB, Chan TH, Dou QP. Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs. Int J Mol Med 2012; 29: 102-6.
155. Zhang XY, Bai QX, Huang GS, Zhao H, Chen JJ, Yang LJ. Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011; 19: 684-8.
156. Ghoneum M, Gollapudi S. Synergistic apoptotic effect of arabinoxylan rice bran(MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro. Neoplasma 2011; 58: 118-23.
157. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB, et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8: 959-70.
158. Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, et al. Curcumin in combination with bortezomib synergistically induced apoptosis inhuman multiple myeloma U266 cells. Mol Oncol 2008; 2: 317-26.
159. Carlson LJ, Cote B, Alani AW, Rao DA. Polymeric micellar codelivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci 2014; 103: 2315-22.
160. Abouzeid AH, Patel NR, Torchilin VP. Polyethylene glycol phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm 2014; 464(1-2): 178-84.
161. Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP. Transferrintargeted polymeric micelles co-loaded with curcumin and paclitaxel: Efficient killing of paclitaxel-resistant cancer cells. Pharm Res 2014; 31: 1938-45.
162. Arzuman L, Beale PZ, Chan C, Yu JQ, Huq F, et al. Synergism from combinations of tris(benzimidazole) monochloroplatinum(II) chloride with capsaicin, quercetin, curcumin and cisplatin in human ovarian cancer cell lines. Anticancer Res 2014; 34: 5453-64.
163. Sarisozen C, Abouzeid AH, Torchilin VP. The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. Eur J Pharm Biopharm 2014; 88: 539-50.
164. Cai YY, Lin WP, Li AP, Xu JY. Combined effects of curcumin and triptolide on an ovarian cancer cell line. Asian Pac J Cancer Prev 2013; 14: 4267-71.
165. Qiu, J, Fu YF, Cheng Q, Cheng XD, Xie X, Lü WG. et al. Reversingpaclitaxel-resistance of SKOV3-TR30 cell line by curcumin. Zhonghua Yi Xue Za Zhi 2012; 92: 1926-8.
166. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009; 6: 928-39.
167. Montopoli M, Ragazzi E, Froldi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif 2009; 42: 195-206.
168. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factorkappaB pathway. Clin Cancer Res 2007; 13: 3423-30.
169. Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 2007; 105: 104-12.
170. Thakkar A, Sutaria D, Grandhi BK, Wang J, Prabhu S. The molecular mechanism of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer. Oncol Rep 2013; 29: 1671-7.
171. Sutaria D, Grandhi BK, Thakkar A, Wang J, Prabhu S. Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. Int J Oncol 2012; 41: 2260-8.
172. Parasramka MA, Gupta SV. Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells. J Oncol 2012: 2012; 709739.
173. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007; 25: 411-8.
174. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-61.
175. Eom DW, Lee JH, Kim YJ, Hwang GS, Kim SN, Kwak JH, et al. Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMB Rep. 2014; 48(8): 461-6.
176. Mathur A, Abd Elmageed ZY, Liu X, Kostochka ML, Zhang H, Abdel-Mageed AB, et al. Mondal D. Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells. PLoS One 2014; 9: e103109.
177. Aditya NP, Shim M, Lee I, Lee Y, Im MH, Ko S. et al. Curcumin and genistein coloaded nanostructured lipid carriers: In vitro digestion and antiprostate cancer activity. J Agric Food Chem 2013; 61: 1878-83.
178. Horie S. Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol 2012; 53: 665-72.
179. Ide, H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 2010; 70: 1127-33.
180. Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AN. et al. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 2006; 27: 475-82.
181. Chatterjee SJ, Pandey S. Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol Ther 2011; 11: 216-28.
182. Kunnumakkara AB, Anand P, Aggarwal BB. Nuclear Factor-κB and chemoresistance: How intertwined are they? In: Mehta K, Siddik ZH, editors. Drug Resistance in Cancer Cells: Springer Science 2009, p. 177-208.
183. Guo O, Yang Y, Wei J, Zhao Q, Luo F, Qian Z. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles. J Biomed Nanotechnol 2014; 10: 227-37.
184. Singh M, Ramos I, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, et al. Curcumin improves the therapeutic efficacy of Listeriaat-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. Cancer Med 2013; 2: 571-82.
185. Faião-Flores F, Suarez JA, Pardi PC, Maria DA. DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1, 4-dienyl]-2-methoxyphenolate: A curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment. Tumour Biol 2011; 33: 775-85.
186. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 2011; 30: 3139-52.
187. Murakami A, Furukawa I, Miyamoto S, Tanaka T, Ohigashi H. Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis. Biofactors 2013; 39: 221-32.
188. Shpitz B Giladi N, Sagiv E, Lev-Ari S, Liberman E, Kazanov D, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006; 74: 140-4.
189. Xu G, Huang W, Zhang WM, Lai ZS, He MR, Wang YD, et al. Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression indimethylhydrazine-induced rat colon carcinogenesis. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 48-52.
190. Li N, Chen X, Liao J, Yang G, Wang S, Josephson Y, et al. Inhibition of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 2002; 23: 1307-13.
191. Nasr M, Selima E, Hamed O, Kazem A. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharmacol 2014; 723: 267-75.
192. Sehgal A, Kumar M, Jain M, Dhawan. Modulatory effects of curcumin in conjunction with piperine on benzo(a)pyrene-mediated DNA adducts and biotransformation enzymes. Nutr Cancer 2013; 65: 885-90.
193. Anand K, Sarkar A, Kumar A, Ambasta RK, Kumar P. Combinatorial antitumor effect of naringenin and curcumin elicit angioinhibitory activities in vivo. Nutr Cancer 2012; 64: 714-24.
194. Sreepriya M, Bali G. Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats Fitoterapia 2005; 76: 549-55.
195. Malhotra A, Nair P, Dhawan DK. Study to evaluate molecular mechanics behind synergistic chemo-preventive effects of curcumin and resveratrol during lung carcinogenesis. PLoS One 2014; 9: e93820.
196. Malhotra A, Nair P, Dhawan DK. Premature mitochondrial senescence and related ultrastructural changes during lung carcinogenesis modulation by curcumin and resveratrol. Ultrastruct Pathol 2012; 36: 179-84.
197. Malhotra A, Nair P, Dhawan DK. Curcumin and resveratrol in combination modulates benzo(a)pyrene-induced genotoxicity during lung carcinogenesis. Hum Exp Toxicol 2010; 31: 1199-206.
198. Malhotra A, Nair P, Dhawan DK. Curcumin and resveratrol synergistically stimulate p21 and regulate cox-2 by maintaining adequate zinc levels during lung carcinogenesis. Eur J Cancer Prev 2011; 20: 411-6.
199. Malhotra A, Nair P, Dhawan DK. Modulatory effects of curcumin and resveratrol on lung carcinogenesis in mice. Phytother Res 2010; 24: 1271-7.
200. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 2010; 99: 4630-41.
201. Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV, et al. Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer 2008; 60: 81-9.
202. Khor TO, Keum YS, Lin W, Kim JH, Hu R, Shen G, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 2006; 66: 613-21.
203. Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B, et al. Murine prostate cancer inhibition by dietary phytochemicals curcumin and phenyethyl isothiocyanate. Pharm Res 2008; 25: 2181-9.
204. Andrzejewski T, Deeb D, Gao X, Danyluk A, Arbab AS, Dulchavsky SA, et al. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol Res 2008; 17: 257-67.
205. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al. Phase I dose escalationtrial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol 2010; 9: 8-14.
206. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006; 4: 1035-8.
207. Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. et al. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. J Oncol Pharm Pract 2012; 18: 186-90.
208. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62: 1137-41.
209. Teiten MH, Dicato M, Diederich M. Hybrid curcumin compounds: A new strategy for cancer treatment. Molecules 2014; 19: 20839-63.
210. Banik B, Somyajit K, Nagaraju G, Chakravarty AR. Oxovanadium(IV) complexes of curcumin for cellular imaging and mitochondria targeted photocytotoxicity. Dalton Trans 2014; 43: 13358-69.
211. Singh DV, Agarwal S, Singh P, Godbole MM, Misra K. Curcumin conjugates induce apoptosis via a mitochondrion dependent pathway in mcf-7 and mda-mb-231 cell lines. Asian Pac J Cancer Prev 2013; 14: 5797-804.
212. Balaji B, Somyajit K, Banik B, Nagaraju G, Chakravarty AR. Photoactivated DNA cleavage and anticancer activity of oxovanadium(iv) complexes of curcumin. Inorg Chim Acta 2013; 400: 142-50.
213. Juneja M, Vanam U, Paranthaman S, Bharathan A, Keerthi VS, Reena JK, et al. 4-amino-2-arylamino-5-indoloyl/cinnamoythiazoles, analogs of topsentin-class of marine alkaloids, induce apoptosis in hela cells. Eur J Med Chem 2013; 63: 474-83.
214. Banerjee S, Prasad P, Hussain A, Khan I, Kondaiah P, Chakravarty AR. et al. Remarkable photocytotoxicity of curcumin in hela cells in visible light and arresting its degradation on oxovanadium(iv) complex formation. Chem Commun 2012; 48: 7702-4.
215. Dubey SK, Sharma AK, Narain U, Misra K, Pati U. Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties. Eur J Med Chem 2008; 43: 1837-46.
216. Mishra S, Kapoor N, Mubarak AA, Pardhasaradhi BV, Kumari AL, Khar A, et al. Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic Biol Med 2005; 38: 1353-60.
217. Vyas HK, Pal R, Vishwakarma R, Lohiya NK, Talwar GP. Selective killing of leukemia and lymphoma cells ectopically expressing HCGβ by a conjugate of curcumin with an antibody against HCGβ subunit. Oncology 2009; 76: 101-11.
218. Liu K, Zhang D, Chojnacki J, Du Y, Fu H, Grant S, et al. Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Org Biomol Chem 2013; 11: 4757-63.
219. Aggarwal S, Ndinguri MW, Solipuram R, Wakamatsu N, Hammer RP, Ingram D, et al. [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo. Int J Cancer 2011; 129: 1611-23.
220. Shi Q, Wada K, Ohkoshi E, Lin L, Huang R, Morris-Natschke SL, et al. Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgens. Bioorg Med Chem 2012; 20: 4020-31.
221. Koon H, Leung AW, Yue KK, Mak NK. Photodynamic effect of curcumin on npc/cne2 cells. J Environ Pathol Toxicol Oncol 2006; 25: 205-15.
222. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. Cancer Res Treat 2014; 46: 2-18.
223. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010; 79: 330-8.
224. FRESHPATENTS, New patents & Technology available at: http: //www. freshpatents. com/http: //tgs. freshpatents. com/Curcuminbx1. php (Accessed on: September 18, 2015).
225. Antony, B. Composition to enhance the bioavailability of curcumin. US20150157718 (2015), US20150037442 (2015), US20140093594 (2014) & US20140088200 (2014).
226. Antony, B. Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof. US20140371327 (2014) & US20140099390 (2014).
227. Antony, B. Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof. US20140193533 (2014).
228. Cave, H. G. Complexes and compositions containing curcumin. US20150110866 (2015), US20150104503 (2015).
229. Helson, L. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders. US20150147385 (2015).
230. Helson, L. Intravenous infusion of curcumin and a calcium channel blocker. US20140234402 (2014).
231. Rawat, D. S., Wang, B., Kumar, N., Manohar, S., Yang, X., Sun, G. et al. Curcumin analogs and methods of making and using thereof. US20150152056 (2015).
232. Senn, S., Rachman, I. Cancer therapeutics. US20150110877 (2015).
233. Alleyne, C. H., Dhandapani, K. M., Wen, K., Ma, M., Hu, W. Protective effects of curcumin against hemorrhagic stroke injury. US20150087705 (2015).
234. Qian, X. Certain chemical entities, compositions, and methods. US20150072984 (2015).
235. Brownell, L. A., Chu, M., Hong, M., Hyun, E., Jia, Q., Jiao, P. Hyun-Jin, K., Mi-Ran, K., Tae-Woo, K., Bo-Su, L., Young-Chul, L., Breanna, M., Jeong-Bum, N., Mi-Sun, O., Mi-Hye, P., Mesfin, Y., Qian, Z. Compositions and methods for joint health. US20150072953 (2015).
236. Jankowitz, S. N., Chopra, R. K. Anti-inflammatory composition. US20150056176 (2015).
237. Gennari, G., Panfilo, S. Pharmaceutical compositions containing phosphatidylserine and curcumin. US20150038467 (2015).
238. Chen, Q. Therapeutic uses of curcumin analogs for treatment of prostate cancer. US20150017720 (2015).
239. Jagt, D. L. V., Deck, L. M., Abcouwer, S. F., Orlando, R. A., Royer, R. E., Waylon M. W. Ekaterina, B.-M, Lucy, H. Therapeutic curcumin derivatives. US20150011494 (2015).
240. Pattayi, A. J., Jayaprabha, K. N. Curcumin coated magnetite nanoparticles for biomedical applications. US20140369938 (2014).
241. Varani, J., Johnson, K. J. Use of two botanicals with complementary activities for improvement of skin. US20140328956 (2014).
242. Kurzrock, R., Li, L., Mehta, K., Aggarawal, B. B., Helson, L. Liposomal curcumin for treatment of diseases. US20140322303 (2014).
243. Sarkar, F. H., Padhye, S. Novel analogs of curcumin and methods of use. US20140303109 (2014).
244. Chaniyilparampu, R. N., Nair, A. K., Parthasarathy, K., Gokaraju, G. R., Gokaraju, R. R., Bhupathiraju, K, Venkata, N. S. R. R. M., Nirvanashetty, S. Curcuminoids and metabolites thereof for treating allergic nasal conditions. US20140271883 (2014).
245. Tummala, H., Kumar, S. Curcuminoid complexes with enhanced stability, solubility and/or bioavailability. US20140271530 (2014).
246. Alperi, J. D., Bosca, A. A. R., Bernd, A. Method for improving the efficacy of curcuminoids and their analogs. US20140257170 (2014).
247. Chauhan, S., Jaggi, M., Yallapu, M. M. Curcumin formulations and methods for making such formulations. US20140228318 (2014).
248. Payne, A. J., Kurien, B. T., Scofield, R. H. Solubilization of cucurminoid compounds and products thereof. US20140161915 (2014).
249. Barthomeuf, C., Chollet, P., Planchat, E., Cure, H. Methods and pharmaceutical compositions for the treatment of hormonerefractory prostate cancers. US20140142168 (2014).
250. Barthomeuf, C., Chollet, P., Bayet-Robert, M. Curcuminoids in combination docetaxel for the treatment of cancer and tumour metastasis. US20140128337 (2014).
251. Ranjan, A. P., Mukerjee, A., Vishwanatha, J. K., Helson, L. Curcumin-er, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy. US20140065061 (2014).
252. Gately, S. T., Triezenberg, S. J., Wang, T. Solid forms of curcumin. US20140031403 (2014).
253. Madhavamenon, K. I., Paulose, M. B. Curcuminoid composition with enhanced bioavailability and a process for its preparation. US20140010903 (2014).